We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
OSI Pharmaceuticals has been issued a U.S. patent covering the production process
for a crystalline polymorph of its cancer drug Tarceva (erlotinib HCl).
Focalin XR (dexmethylphenidate HCl), developed jointly by Novartis Pharmaceuticals
and Celgene, has been approved by the FDA as a treatment for attention-deficit/hyperactivity
disorder (ADHD) in adults, adolescents and children.
The FDA has approved Abbott Laboratories' Zemplar capsules, an oral, activated
vitamin D therapy for prevention and treatment of secondary hyperparathyroidism
(SHPT).
Portola Pharmaceuticals has entered into a license agreement with Astellas Pharma
to advance the development of a series of promising preclinical compounds developed
by Astellas.
CardioVascular BioTherapeutics (CVBT) has announced that its preclinical animal
studies showed positive results for its drug candidate Cardio Vascu-Grow for
wound healing in diabetic mice.
PediaMed - The Pediatrics Company has enrolled the first patient in a Phase
II research study to evaluate an investigational medication for treatment of
persistent gastrointestinal (GI) dysfunction in autistic children.
Favrille has announced that the first patient has been enrolled in a physician-sponsored
Phase II clinical trial evaluating the company's lead product candidate, FavId.